京都薬科大学
生化学分野

Laboratory of Biochemistry and Molecular Biology

細胞分裂制御機構とEphA2シグナルの解析から
疾患の分子機構解明と創薬への展開を目指す

Elucidating Mitotic Control and EphA2 Signaling Toward Therapeutic Development

〒607-8414 京都市山科区御陵四丁野町1
教授 中山 祐治
nakayama♬mb.kyoto-phu.ac.jp

研究概要

京都薬科大学 生化学分野 中山研では、細胞分裂制御機構および EphA2シグナルの分子機構を細胞生物学・分子生物学的手法を用いて研究しています。

Keywords
Mitotic control / EphA2 / Ephexin4 / RhoG / Cell cycle / Cancer biology

 

EphA2 and Cell Division


Our research focuses on how EphA2 signaling regulates cell division and cancer progression.
Our goal is to understand the molecular mechanisms by which EphA2 regulates cell division and to explore its potential as a therapeutic target in cancer.


 

EphA2 is a member of the Eph receptor family, the largest family of receptor tyrosine kinases, and plays important roles in regulating cell proliferation and migration during development and tissue formation. Its ligand, ephrin-A1, mediates cell–cell repulsion that guides tissue patterning. Although EphA2 expression is generally low in adult tissues, it is frequently overexpressed in a wide range of cancers, including colorectal, lung, pancreatic, and breast cancers, as well as metastatic melanoma.

 

In cancer cells, EphA2 can be activated independently of ligand binding, promoting growth, survival, and migration through multiple signaling pathways. Our research has revealed that during cell division, EphA2 Ser897 is phosphorylated through the CDK1–MEK/ERK–RSK signaling cascade. This phosphorylation regulates spindle formation and cortical stiffness via activation of Ephexin4/RhoG. These findings indicate that EphA2 plays important roles not only in cancer progression but also in the regulation of normal cell division.

 

Moreover, we recently found that EphA2 is upregulated in response to DNA damage and suppresses p53/p21 transcriptional activation. Knockdown of EphA2 induces p21 upregulation under DNA damage conditions. As a result, a subset of cells undergoes mitotic bypass instead of G2 arrest, leading to suppression of cell proliferation. Interestingly, these effects were observed in cervical cancer cell lines but not in colorectal or breast cancer cell lines. These findings suggest that EphA2 signaling plays a previously unrecognized role in determining cell fate after DNA damage and may provide new insights into anti-cancer strategies for certain cancer types.